Atlas Trials

Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years

Clinical trial NCT05231590 · COMPLETED

Trial details

NCT number
NCT05231590
Sponsor
Cinnagen
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
COVID-19
Start date
2022-02-23
Primary completion
2022-04-14
Enrollment
581

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.